Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
TUCSON, Ariz., April 27, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market close on Thursday, May 10. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | ||
| Date: | Thursday, May 10 | |
| Time: | 4:30pm Eastern Time | |
| Toll Free: | 866-548-4713 | |
| International: | 323-794-2093 | |
| Conference ID: | 5477857 | |
| Webcast: | http://public.viavid.com/index.php?id=129155 | |
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
[email protected]
TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
[email protected]
